Literature DB >> 2307991

Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.

S Cortelazzo1, P Viero, G Finazzi, A D'Emilio, F Rodeghiero, T Barbui.   

Abstract

The purpose of this study was to determine which factors were associated with an increased risk of thrombo-hemorrhagic complications in a historical cohort of 100 consecutive and unselected patients with essential thrombocythemia (ET) in whom busulfan treatment was given when platelets were more than 1,000 x 10(9)/L and/or a major thrombotic or hemorrhagic event occurred. The incidence of major hemorrhagic complications was very low (0.33%/person-time at risk [pt-yr]) in comparison with that of thrombotic episodes (6.6%/pt-yr). In an adequate and appropriate control historical group of 200 patients, no severe hemorrhages were recorded and the incidence of thrombotic events was 1.2% pt-yr. Thus, the analysis of risk factors was restricted to this latter group of events. Age, a previous thrombotic event, and long duration of thrombocytosis were identified as major risk factors for thrombosis, while smoking, diabetes mellitus, hyperlipidemia, and hypertension did not influence the rate of thrombotic episodes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2307991     DOI: 10.1200/JCO.1990.8.3.556

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  60 in total

1.  Neurological disorders in essential thrombocythemia.

Authors:  Segolene Billot; Eirini G Kouroupi; Johan Le Guilloux; Bruno Cassinat; Caroline Jardin; Thierry Laperche; Pierre Fenaux; Antoine F Carpentier; Jean-Jacques Kiladjian
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

Review 2.  Management of myeloproliferative neoplasms: from academic guidelines to clinical practice.

Authors:  Giovanni Barosi; Letizia Lupo; Vittorio Rosti
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

3.  Left main coronary thrombosis with essential thrombocythemia.

Authors:  Zekeriya Nurkalem; Nevzat Uslu; Sevket Gorgulu; Mehmet Eren
Journal:  J Thromb Thrombolysis       Date:  2006-12       Impact factor: 2.300

4.  Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?

Authors:  Tiziano Barbui; Alessandra Carobbio; Alessandro Rambaldi; Guido Finazzi
Journal:  Blood       Date:  2009-04-16       Impact factor: 22.113

5.  Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials.

Authors:  John Mascarenhas; Ruben Mesa; Josef Prchal; Ronald Hoffman
Journal:  Haematologica       Date:  2014-06       Impact factor: 9.941

6.  Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia.

Authors:  Andrea Piccin; Michael Steurer; Manfred Mitterer; Elisabeth Maria Blöchl; Luigi Marcheselli; Irene Pusceddu; Alessandra Marabese; Irene Bertozzi; Daisy Corvetta; Maria Luigia Randi; Elena Elli; Enrico Maria Pogliani; Dino Veneri; Omar Perbellini; Mauro Krampera; Enrica Pacquola; Michele Gottardi; Mario Tiribelli; Anna Guella; Barbara Innella; Paolo Vivaldi; Ercole De Biasi; Rosaria Sancetta; Roberta Rocconi; Renato Bassan; Filippo Gherlinzoni; Giovanni Pizzolo; Günther Gastl; Sergio Cortelazzo
Journal:  Intern Emerg Med       Date:  2015-01-14       Impact factor: 3.397

7.  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Giovanni Barosi; Gunnar Birgegard; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben Mesa; Mary F McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Andreas Reiter; Richard T Silver; Srdan Verstovsek; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

8.  Erythromelalgia as a presenting manifestation in a patient with essential thrombocythemia complicating renovascular hypertension due to unilateral renal artery stenosis.

Authors:  Jin-Wuk Hur; Young-Yiul Lee; Woong-Soo Lee; Jae-Bum Jun
Journal:  Rheumatol Int       Date:  2005-03-05       Impact factor: 2.631

9.  Essential thrombocytemia and ischemic stroke: report of six cases.

Authors:  L Casto; M Camerlingo; G Finazzi; B Censori; T Barbui; A Mamoli
Journal:  Ital J Neurol Sci       Date:  1994-10

10.  Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.

Authors:  Heinz Gisslinger; Mirjana Gotic; Jerzy Holowiecki; Miroslav Penka; Juergen Thiele; Hans-Michael Kvasnicka; Robert Kralovics; Petro E Petrides
Journal:  Blood       Date:  2013-01-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.